Share Capital and Share Premium

12 Months Ended

Dec. 31, 2025

12. Share Capital and Share Premium

As of December 31, 2025, the Company’s share capital was represented by 61,883,306 shares. All shares were issued,

fully paid up and of the same class. The table below summarizes the share issuances as a result of offerings, exercise of

stock options and the vesting of restricted stock units under the Company’s Employee Stock Option Plan.

Roll forward of number of shares outstanding:


Number of shares outstanding on January 1, 2023		55,395,856
Exercise of stock options		1,137,439
Vesting of RSUs		79,560
Global public offering on Nasdaq on July 18, 2023		2,244,899
Over-allotment option exercised by underwriters on July 19, 2023		336,734
Number of shares outstanding on December 31, 2023		59,194,488
Exercise of stock options		1,478,225
Vesting of RSUs		88,244
Number of shares outstanding on December 31, 2024		60,760,957
Exercise of stock options		986,507
Vesting of RSUs		135,842
Number of shares outstanding on December 31, 2025		61,883,306

On July 18, 2023, argenx SE offered 2,244,899 of its ordinary shares through a global offering which consisted of

1,580,981 ADSs in the U.S. at a price of $490.00 per ADS, before underwriting discounts and commissions and offering

expenses; and 663,918 ordinary shares in the European Economic Area at a price of €436.37 per share, before

underwriting discounts and commissions and offering expenses. On July 19, 2023, the underwriters of the offering

exercised their overallotment option to purchase 336,734 additional ADSs in full. As a result, argenx SE received $1.3

billion in gross proceeds from this offering, decreased by $66 million of underwriter discounts and commissions, and

offering expenses, of which $1 million has been deducted from equity. The total net cash proceeds from the offering

amounted to $1.2 billion.

On May 27, 2025, at the annual general meeting, the shareholders of the Company approved the authorization to the

Board to issue up to a maximum of 10% of the then-outstanding share capital, for a period of 18 months.

On December 31, 2025, an amount of €532,863, represented by 5,328,634 shares, still remained available under the

authorization to issue shares as granted to the Board by the shareholders of the Company.